SGC-UNC is not-for-profit, public-private partnership that performs basic science of relevance to drug discovery. The scientific focus is the chemical biology of the dark proteome to create chemical inhibitors and screening assays to explore the biology of these understudied proteins from the human genome in health and disease. A chemogenomic set contained 367 small molecule kinase inhibitors that were previously published by chemists at GSK (named as Published Kinase Inhibitor Set (PKIS)) and was carefully selected to maximize chemical and biological diversity of the inhibitors was made available to the scientific community as a resource to study kinase biology and to uncover potential new targets for drug discovery. Broad profiling at NanoSyn and the SGC Oxford showed that PKIS had activity across over 150 human kinases. PKIS To date over 50 peer-reviewed papers have been published that report on the use of PKIS in the biomedical research. A second chemogenomics set of kinase inhibitors from GSK, Takeda, and Pfizer was assembled as PKIS2 which contained 645 inhibitors and included many additional chemotypes that were not represented in the original set was also made widely available to the scientific community. PKIS2 was profiled using the DiscoverX KINOMEscan affinity capture technology and shown to index 250 human kinases. Learn more…